• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃复安所致帕金森综合征。10例临床特征

Metoclopramide-induced Parkinsonism. Clinical characteristics of ten cases.

作者信息

Indo T, Ando K

出版信息

Arch Neurol. 1982 Aug;39(8):494-6. doi: 10.1001/archneur.1982.00510200036006.

DOI:10.1001/archneur.1982.00510200036006
PMID:7103798
Abstract

Clinical characteristics of ten patients with metoclopramide hydrochloride-induced parkinsonism were studied. This condition was found to be more common in aged women and developed subacutely with bilateral symptoms. Clinically, metoclopramide-induced parkinsonism is sometimes accompanied by a rest tremor and may therefore be confused with Parkinson's disease. It is distinct from the latter in that orolingual dyskinesia and postural tremor are often found before the administration of antiparkinsonian drugs. The patients with metoclopramide-induced parkinsonism made a complete recovery within a few months after administration of the drug was discontinued.

摘要

对10例盐酸甲氧氯普胺所致帕金森综合征患者的临床特征进行了研究。发现这种情况在老年女性中更为常见,呈亚急性起病,伴有双侧症状。临床上,甲氧氯普胺所致帕金森综合征有时伴有静止性震颤,因此可能与帕金森病混淆。它与后者的不同之处在于,在使用抗帕金森病药物之前,常出现口面部运动障碍和姿势性震颤。停用该药物后,甲氧氯普胺所致帕金森综合征患者在几个月内完全康复。

相似文献

1
Metoclopramide-induced Parkinsonism. Clinical characteristics of ten cases.胃复安所致帕金森综合征。10例临床特征
Arch Neurol. 1982 Aug;39(8):494-6. doi: 10.1001/archneur.1982.00510200036006.
2
Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases.甲氧氯普胺致血液透析患者帕金森综合征。两例报告。
Arch Intern Med. 1986 Oct;146(10):2070-1.
3
[Severe parkinsonism due to metoclopramide: the importance of early recognition].[甲氧氯普胺所致严重帕金森症:早期识别的重要性]
Ned Tijdschr Geneeskd. 2013;157(26):A6037.
4
Asymmetry in clinical features of drug-induced parkinsonism.药物性帕金森综合征临床特征的不对称性。
J Neuropsychiatry Clin Neurosci. 1990 Winter;2(1):64-6. doi: 10.1176/jnp.2.1.64.
5
Adverse neurologic effects of metoclopramide.甲氧氯普胺的不良神经效应。
Can Med Assoc J. 1982 Jan 1;126(1):23-5.
6
Metoclopramide-induced parkinsonism.甲氧氯普胺所致帕金森综合征。
South Med J. 1989 Dec;82(12):1581-2. doi: 10.1097/00007611-198912000-00033.
7
Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.帕金森病的运动和非运动特征可预测持续性药物诱导的帕金森病。
Parkinsonism Relat Disord. 2014 Jul;20(7):738-42. doi: 10.1016/j.parkreldis.2014.03.024. Epub 2014 Apr 1.
8
[Four cases of metoclopramide-induced parkinsonism].[4例胃复安所致帕金森综合征]
Nihon Naika Gakkai Zasshi. 1986 Apr;75(4):533-6. doi: 10.2169/naika.75.533.
9
Metoclopramide-induced encephalopathy in Parkinson disease.帕金森病中胃复安诱发的脑病
South Med J. 2010 Feb;103(2):178-80. doi: 10.1097/SMJ.0b013e3181ca9b3f.
10
Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy.
N Engl J Med. 1981 Dec 3;305(23):1417. doi: 10.1056/nejm198112033052316.

引用本文的文献

1
A refractory head tremor appearing after volatile anesthesia combined with epidural anesthesia in a patient with spinocerebellar ataxia type 6.一名患有6型脊髓小脑共济失调的患者在挥发性麻醉联合硬膜外麻醉后出现难治性头部震颤。
JA Clin Rep. 2018 Jan 30;4(1):13. doi: 10.1186/s40981-018-0150-9.
2
Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism.胃复安作为糖尿病胃轻瘫的促动力药物:重新审视帕金森症风险
Ther Adv Drug Saf. 2019 Jun 20;10:2042098619854007. doi: 10.1177/2042098619854007. eCollection 2019.
3
High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study.
高暴露量与标准暴露量的甲氧氯普胺相比,帕金森病的风险更高:一项全国基于人群的队列研究。
Br J Clin Pharmacol. 2018 Sep;84(9):2000-2009. doi: 10.1111/bcp.13630. Epub 2018 Jun 19.
4
Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.抗帕金森病药物:临床显著的药物相互作用和不良反应及其管理。
CNS Drugs. 1998 Apr;9(4):291-310. doi: 10.2165/00023210-199809040-00005.
5
Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.帕金森病及其管理:第1部分:疾病实体、危险因素、病理生理学、临床表现及诊断。
P T. 2015 Aug;40(8):504-32.
6
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.系统评价:用于胃肠道疾病的 5-HT(4)激动剂的心血管安全性概况。
Aliment Pharmacol Ther. 2012 Apr;35(7):745-67. doi: 10.1111/j.1365-2036.2012.05011.x. Epub 2012 Feb 22.
7
Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management.帕金森病患者的胃肠动力问题。抗帕金森病治疗的效果及管理指南。
Drugs Aging. 1997 Apr;10(4):249-58. doi: 10.2165/00002512-199710040-00002.
8
Drug-induced movement disorders.药物性运动障碍
Drug Saf. 1997 Mar;16(3):180-204. doi: 10.2165/00002018-199716030-00004.
9
Antiparkinsonian agents. Drug interactions of clinical significance.抗帕金森病药物。具有临床意义的药物相互作用。
Drug Saf. 1996 May;14(5):343-54. doi: 10.2165/00002018-199614050-00006.
10
Anti-parkinsonian drugs today.当今的抗帕金森病药物。
Drugs. 1984 Sep;28(3):236-62. doi: 10.2165/00003495-198428030-00002.